|
Status |
Public on Jul 14, 2015 |
Title |
NCI-H1930 |
Sample type |
genomic |
|
|
Source name |
SCLC cell line
|
Organism |
Homo sapiens |
Characteristics |
cell line: NCI-H1930
|
Treatment protocol |
No treatment
|
Growth protocol |
cell lines: RPMI with 10%FBS
|
Extracted molecule |
genomic DNA |
Extraction protocol |
All the procedure of bisulfite conversion, amplification, labeling and hybridization was performed following the protocol provided by Illumina
|
Label |
Cy5 and Cy3
|
Label protocol |
standard Illumina protocol
|
|
|
Hybridization protocol |
standard Illumina protocol
|
Scan protocol |
standard Illumina protocol
|
Data processing |
Data was processed and normalized using GenomeStudio V2011.1
|
|
|
Submission date |
Feb 25, 2015 |
Last update date |
Jul 14, 2015 |
Contact name |
David Soong |
Organization name |
GlaxoSmithKline
|
Street address |
1250 S Collegeville Rd
|
City |
Collegeville |
State/province |
PA |
ZIP/Postal code |
19426 |
Country |
USA |
|
|
Platform ID |
GPL13534 |
Series (2) |
GSE66295 |
A DNA Hypomethylation Signature Predicts Novel Anti-Tumor Activity of LSD1 Inhibitors in SCLC (BeadChip) |
GSE66298 |
A DNA Hypomethylation Signature Predicts Novel Anti-Tumor Activity of LSD1 Inhibitors in SCLC |
|